Tag Archives: cabazitaxel

New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

Posted on March 5, 2012 by wngai

Excellent news for prostate cancer patients whose cancer has progressed after hormonal treatment and chemotherapy!   An experimental oral agent, MDV3100 (Medivation) was found to improve survival in metastatic castration-resistant prostate cancer by 4.8 months The new agent, called MDV3100, is … Continue reading →

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , , , , , , , , , | Comments Off on New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

New Prostate Cancer Drug Approved by FDA

Posted on May 30, 2011 by wngai

Good news for patients with metastatic prostate cancer.  The FDA (US Food and Drug Administration) has approved Johnson & Johnson’s Zytiga (abiraterone) in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy.  Abiraterone … Continue reading →

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , | 1 Comment

New Chemotherapy, Cabazitaxel (Jevtana), for Advanced Prostate Cancer

Posted on July 4, 2010 by wngai

A new chemotherapy, Cabazitaxel (Jevtana) has been approved in the United States to treat men who have advanced hormone-refractory prostate cancer and have failed docetaxel. The approval was based on the results of the phase 3 TROPIC clinical study, which … Continue reading →

Posted in Cancer, Prostate cancer | Tagged , , , , , , , | Comments Off on New Chemotherapy, Cabazitaxel (Jevtana), for Advanced Prostate Cancer